Lumigan in Mexico: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in Mexico under the regulatory framework of COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- Currency
- MXN
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in Mexico
Mexico has a tiered Rx system: medications classified as Group IV require prescription and are dispensed under pharmacy oversight; Group V is OTC. Antibiotics moved to strict prescription enforcement in 2010. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in Mexico follows the standard rules of COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).
Pharmacy dispensing
Major chains (Farmacias del Ahorro, Farmacias Similares, Benavides) and independent farmacias dispense across Mexico. Many chain pharmacies offer adjacent low-cost consultations. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online pharmacy in Mexico is growing through both chain platforms and dedicated services; legal Rx fulfilment requires verified prescriptions and COFEPRIS-licensed pharmacies. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in MXN
Retail pricing in Mexico depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in Mexico? ▾
Mexico has a tiered Rx system: medications classified as Group IV require prescription and are dispensed under pharmacy oversight; Group V is OTC. Antibiotics moved to strict prescription enforcement in 2010. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).
Is generic Lumigan available in Mexico? ▾
Authorised generics of Bimatoprost are typically available in Mexico at a lower cost than branded Lumigan, with bioequivalence required by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in MXN? ▾
Prices in MXN vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Mexico.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.